Verge Genomics – Tech Innovator Profile
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Founded in 2015, Verge Genomics is an AI-driven biopharmaceutical drug discovery company that applies patient genomes, epigenomics, and gene expression for identifying novel effective drugs; stratify patient subpopulations, and therapeutic gene targets for accelerating clinical success. Verge Genomics is focusing on three neurodegenerative diseases: frontotemporal dementia (FTD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS).
Scope
The report provides information and insights into Verge Genomics, including –
– Overview of the company and its product offering
– Detailed insight into its business model, company type and headquarter
– Information on funding and partnership
– Biography of top management
Reasons to Buy
– Gain insights into Verge Genomics' business operations.
– Gain insights into partnership and funding.
– Gain understanding about its technology focus.
Sheffield Institute for Translational Neuroscience (SITraN)
Genomics England
Datavant
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.